This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. . Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Richard J Wheeler: Innovator in Neurodegenerative Disease Treatment
Introduction
Richard J Wheeler is a notable inventor based in Oxford, GB. He has made significant contributions to the field of medical science, particularly in the treatment of neurodegenerative diseases. His innovative work focuses on compounds that can prevent or treat conditions associated with the formation of stress granules.
Latest Patents
Richard J Wheeler holds 1 patent for his invention titled "Compounds for treatment of diseases and methods of screening therefor." This patent relates to a compound designed for the prevention or treatment of neurodegenerative diseases. The compounds he has identified include lipoic acid, lipoamide, dihydrolipoic acid, and dihydrolipoamide. The invention also outlines a method for identifying compounds that modulate characteristics associated with condensates, which are crucial in understanding cellular processes.
Career Highlights
Wheeler is affiliated with the Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V., where he continues to advance research in his field. His work has the potential to impact the treatment of various neurodegenerative diseases, making him a key figure in medical innovation.
Collaborations
Richard J Wheeler has collaborated with esteemed colleagues such as Anthony A Hyman and Marc Bickle. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic approaches.
Conclusion
Richard J Wheeler's contributions to the field of neurodegenerative disease treatment exemplify the importance of innovation in medical science. His work not only advances our understanding of these diseases but also opens new avenues for potential therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
